Oncothyreon has filed an IND for its phosphatidylinositol-3-kinase (PI3K) inhibitor PX-866 for the treatment of advanced cancers.
Filed under: kinase | Tagged: kinase, Oncothyreon, PI3K, PX-866, PX866 | Leave a Comment »
Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2- Providing a resource for information on kinase inhibitors
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
